Search Results - "Agbarya, A."

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer by Dudnik, E., Agbarya, A., Grinberg, R., Cyjon, A., Bar, J., Moskovitz, M., Peled, N.

“…Background Brigatinib is a potent ROS1 inhibitor. The existing data on its clinical activity in ROS1-rearranged non-small cell lung cancer (NSCLC) are limited…”
Get full text

Stepping from traditional to integrative medicine: perspectives of Israeli-Arab patients on complementary medicine's role in cancer care by Ben-Arye, E., Massalha, E., Bar-Sela, G., Silbermann, M., Agbarya, A., Saad, B., Lev, E., Schiff, E.

“…Limited research is available on the perspectives of patients with cancer regarding integration of complementary medicine (CM) in conventional supportive…”
Get full text

794: Crizotinib is an allosteric ABL-inhibitor targeting both native BCR/ABL and BCR/ABL-T315I in vitro and in vivo models of PH+ leukemia by Mahajna, J, Khamaisie, H, Ruimi, N, Agbarya, A, Eshel, E, Dally, N, Ottmann, O, Biondi, R, Mian, A.A, Ruthardt, M

Get full text

1394P Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations by Janzic, U., Shalata, W., Agbarya, A., Dziadziuszko, R., Szymczak, K., Jakopovic, M., Mountzios, G., Pluzanski, A.

Get full text

15P FGFR3-TACC3 fusion (F) as an acquired resistance mechanism following treatment with EGFR TKIs and a suggested novel target in aNSCLC by Ari, R., Dudnik, E., Hershkovitz, D., Jain, S.S., Soussan-Gutman, L., Ben Shitrit, T., Nechushtan, H., Peled, N., Agbarya, A.

Get full text

3044 Mistletoe as complementary treatment in patients with advanced non- small-cell lung cancer (NSCLC) treated with carboplatin/gemcitabine combination: a randomized phase II study by Bar-Sela, G, Wollner, M, Agbarya, A, Zwergel, L, Maykler, I, Sharvit, L, Kuten, A, Haim, N

Get full text

1683P SARS-CoV-2 infection and lung cancer management in Europe by Agbarya, A., Addeo, A., Charpidou, A., Araújo, A., Cuppens, K., Brustugun, O.T., Rajer, M., Jakopovic, M., Marinca, M.V., Pluzanski, A.

Get full text

74P A predictive signature for response to immunotherapy in non-small cell lung cancer based on plasma proteomics and clinical parameters by Shaked, Y., Lahav, C., Harel, M., Jacob, E., Sela, I., Yahalom, G., Elon, Y., Sharon, O., Kamer, I., Dicker, A., Bar, J., Katzenelson, R., Wolf, I., Gottfried, M., Abu-Amana, M., Agbarya, A., Nechushtan, H., Moskovits, M.T., Zer, A.

Get full text

158P Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry by Mountzios, G., Planchard, D., Metro, G., Prelaj, A., Tsiouda, D., Shalata, W., Riudavets, M., Christopoulos, P., Girard, N., Albarran Artahona, V.M., Garcia Campelo, M.R., Samitas, K., Banna, G.L., Boukovinas, I., Agbarya, A., Koumarianou, A., Perdikouri, E.I., Kosmidis, P., Reck, M., Lo Russo, G.

Get full text

The importance of fertility preservation in women with early breast cancer by Agbarya, A., Linn, S.

“…Abstract only e20663 Background: Young women with breast cancer often seek advice regarding treatment effects on their fertility. The purpose of this study was…”
Get full text

1022 Dexamethasone, etoposide, ifosfamide, and cisplatin (DVIP) as salvage therapy in low-grade Non Hodgkin's lymphoma (NHL), following prior anthracycline containing therapy by Haim, N., Agbarya, A., Leitzin, L., Ben-Shachar, M., Epelbaum, R.

Get full text